GLP-1 History & Genetic Response Patterns

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonist medications first emerged in 1987 when researchers identified glucagon-like peptide-1's role in glucose regulation. Today, these drugs represent one of medicine's most significant therapeutic advances, with global adoption now extending far beyond their original diabetes indication into weight management and cardiometabolic health.

For patients considering GLP-1 treatment, understanding this medication class's scientific foundation matters—but equally important is recognizing that individual response varies significantly. Genetic factors influence how your body processes these medications and responds to their effects, making personalized assessment a critical step before starting treatment.

The Scientific Origins of GLP-1: From Gut Hormone Discovery to Modern Therapeutics

In 1987, Swedish researcher Jens Juul Holst identified glucagon-like peptide-1 (GLP-1), a naturally occurring hormone secreted by intestinal L-cells in response to nutrient intake. This discovery revealed GLP-1's dual function: stimulating insulin release when blood glucose rises and suppressing glucagon and appetite signaling. This physiologic understanding became the foundation for a new drug class.

The first GLP-1 receptor agonist, exenatide, received FDA approval in 2005 for type 2 diabetes. Its success prompted development of longer-acting formulations and additional agents. By 2021, semaglutide (marketed for weight management as Wegovy) and tirzepatide (combining GLP-1 and GIP receptor activation) demonstrated weight loss efficacy exceeding 20% in clinical trials, fundamentally reshaping obesity treatment.

Three Decades of GLP-1 Development: Key Milestones and Clinical Impact

GLP-1 medication evolution reflects iterative scientific progress. Early injectable formulations required twice-daily dosing; modern agents offer once-weekly administration. Oral formulations emerged in the 2010s, expanding access and convenience. Dual and triple receptor agonists now represent the frontier, targeting multiple metabolic pathways simultaneously to maximize therapeutic benefit.

Year/Period	Development Milestone	Clinical Significance
1987	GLP-1 hormone identified	Foundation for rational drug design
2005	Exenatide FDA approval	First GLP-1 agonist for type 2 diabetes
2014	Liraglutide (Saxenda) approved	First GLP-1 approved specifically for weight management
2021	Semaglutide (Wegovy) Phase 3 results	Demonstrated 16.4 kg average weight loss in 68 weeks
2023	Tirzepatide (Zepbound) approval	Dual GLP-1/GIP agonist showing superior weight loss
2024	Compounded formulations expanded	Increased access and cost-effective alternatives to branded agents

How Genetic Predispositions Shape Individual GLP-1 Response

Research increasingly demonstrates that genetic variation influences how individuals respond to GLP-1 medications. Variants in genes encoding the GLP-1 receptor, GIP receptor, and genes affecting appetite regulation (such as FTO and MC4R) can influence treatment efficacy and side effect tolerance. These aren't deterministic, but they may provide clinically relevant context.

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 and GIP receptor genes (GLP1R rs6923761, GIPR rs1800437) alongside metabolic predisposition markers (FTO rs9939609, MC4R rs17782313). Understanding these genetic predispositions may help providers customize dosing, formulation selection, or combination strategies to align with your individual metabolic profile and response patterns.

Why This History Matters: Making Informed Treatment Decisions Today

GLP-1 medications represent three decades of scientific refinement, regulatory scrutiny, and real-world evidence in millions of patients. This evidence base supports their use for qualifying patients, but also demonstrates significant inter-individual variability in response. Newer, longer-acting formulations with improved tolerability reflect the field's responsiveness to clinical feedback and patient needs.

Before starting GLP-1 treatment, working with a qualified healthcare provider to assess your medical history, current medications, and metabolic markers is essential. Genetic insight into your peptide pathway predispositions can support this conversation, helping your provider select a formulation and dosing strategy aligned with your individual physiology and treatment goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx's approach integrates GLP-1 medication access through licensed 503A compounding pharmacies with optional Precision Peptide Genetic Testing. This combination may help provide context about your individual predispositions in GLP-1 and GIP receptor genes, alongside metabolic genetic factors that influence appetite regulation and weight management response patterns.

The Precision Peptide Genetic Test reveals predispositions in four key gene variants associated with peptide pathway function and metabolic health. These predispositions should be interpreted with a qualified healthcare provider—they indicate susceptibility or likely response patterns, not definitive medication response or health outcomes. Genetic context is one data point among many in treatment planning.

Understanding your genetic predispositions in GLP-1/GIP signaling and metabolic pathways can support a more informed conversation with your healthcare provider about which GLP-1 formulation, dosing strategy, or combination approach may align best with your individual physiology. PlexusDx offers compounded semaglutide and tirzepatide options at $189/mo month-to-month, or from $149/mo on the 6-month plan, with genetic testing available for $99 as an add-on or $298 standalone.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What year does this article give for the identification of the GLP-1 hormone?

The article says GLP-1 was identified in 1987 as a hormone secreted by intestinal L-cells in response to nutrient intake, with the dual function of stimulating insulin release when glucose rises and suppressing glucagon and appetite signaling. Its milestone table lists 1987 as hormone identification, which is a discovery date rather than the arrival of any medication.

Which milestone does the article's table assign to 2014?

The table lists liraglutide approved as Saxenda in 2014 and calls it the first GLP-1 approved specifically for weight management. The surrounding rows run from the 1987 hormone identification through the 2005 exenatide approval, the 2021 Wegovy Phase 3 results, the 2023 Zepbound approval, and expanded compounded formulations in 2024.

How does the article describe the shift in dosing frequency over three decades?

The post says early injectable formulations required twice-daily administration while modern agents offer once-weekly administration. It says oral formulations emerged in the 2010s, expanding access and convenience, and that dual and triple receptor agonists now represent the frontier by targeting multiple metabolic pathways at once. It frames this as iterative progress rather than a single breakthrough.

What does the article's table say about the 2024 entry on compounded formulations?

The table lists 2024 as the year compounded formulations expanded, describing the clinical significance as increased access and cost-effective alternatives to branded agents. The article does not add that compounded products are not FDA-approved finished products and do not inherit the branded products' clinical trial evidence, which is important context for reading that row.

Who does the article credit with identifying GLP-1, and is the attribution accurate?

The post credits researcher Jens Juul Holst with the 1987 identification of GLP-1, but it describes him with the wrong nationality, so the attribution as written should not be reused. The underlying point the article makes is sound: understanding GLP-1's role in insulin release and appetite signaling became the foundation for an entire drug class.

Related Reading

• How Do Genetic Variations Impact Glp 1 Response
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• History Of Glp 1 Drugs Plexusdx
• Glp 1 Medications

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.